白藜芦醇对心血管疾病患者的抗炎作用：随机对照试验的系统评价和荟萃分析。
Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials.
机构信息
Department of Clinical Biochemistry, School of Allied Medical Sciences, Shahroud University of Medical Sciences, Shahroud, Iran.
Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
出版信息
Complement Ther Med. 2022 Nov;70:102863. doi: 10.1016/j.ctim.2022.102863. Epub 2022 Jul 26.
BACKGROUND
Chronic inflammation is one of the most important factors involved in the development and progression of cardiovascular disease (CVDs). Accumulating evidence has described the effect of resveratrol, a natural polyphenolic compound, on biomarkers of inflammation among patients with CVDs; however, findings are controversial. Here we performed a systematic review and meta-analysis of randomized controlled trials to evaluate the effect of resveratrol supplements on TNF-α, IL-6, and CRP levels in CVDs patients.
METHODS
Online research was conducted in the following database: MEDLINE, EMBASE, Cochrane Library, Web of Science databases, and Scopus. This systematic review and meta-analysis were conducted to investigate the effects of resveratrol supplements on inflammatory biomarkers among patients with CVDs. The meta-analysis was performed using Comprehensive Meta-Analysis (CMA) V3 software.
RESULTS
Six RCTs met the inclusion criteria and were selected for the current meta-analysis. Our results demonstrated that resveratrol significantly decreases serum levels of CRP (MD = -0.63, 95 % CI: -0.1.13, -0.12; p = 0.01), and TNF-α (MD = -0.55, 95 % CI: -1.04, -0.06; p = 0.02), however, resveratrol had not significant effect on serum concentration of IL-6 (MD = -0.12, 95 % CI: -0.52, 0.27; p = 0.53), in patients with CVDs.
CONCLUSION
Our results suggest that resveratrol can be used as a potential treatment in patients with CVD by reducing inflammatory conditions.
背景
慢性炎症是心血管疾病（CVDs）发展和进展的最重要因素之一。越来越多的证据描述了白藜芦醇作为一种天然多酚化合物对 CVD 患者炎症生物标志物的影响；然而，研究结果存在争议。在这里，我们进行了一项系统评价和荟萃分析，以评估白藜芦醇补充剂对 CVD 患者 TNF-α、IL-6 和 CRP 水平的影响。
方法
在线研究在以下数据库中进行：MEDLINE、EMBASE、Cochrane 图书馆、Web of Science 数据库和 Scopus。这项系统评价和荟萃分析旨在调查白藜芦醇补充剂对 CVD 患者炎症生物标志物的影响。荟萃分析使用 Comprehensive Meta-Analysis (CMA) V3 软件进行。
结果
符合纳入标准的 6 项 RCT 被选入当前的荟萃分析。我们的结果表明，白藜芦醇显著降低 CRP（MD=-0.63，95%CI：-0.1.13，-0.12；p=0.01）和 TNF-α（MD=-0.55，95%CI：-1.04，-0.06；p=0.02）的血清水平，但白藜芦醇对 IL-6 的血清浓度没有显著影响（MD=-0.12，95%CI：-0.52，0.27；p=0.53），在 CVD 患者中。
结论
我们的结果表明，白藜芦醇通过减轻炎症状态，可以作为 CVD 患者的潜在治疗方法。
Zotero 插件